COLL vs PSA · P/E 17, rev $181.9M vs rev $4.82B
Collegium Pharmaceutical Inc (COLL) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
PSA (PSA) common stock.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. PSA currently screens at market cap $0.
Not investment advice. Open the COLL and PSA stock pages for the full models.
Not investment advice.